SARS-CoV-2 Spike-specific binding and neutralizing antibodies, elicited either by natural infection or vaccination, have emerged as potential correlates of protection. An important question, however, is whether vaccine-elicited antibodies in humans provide direct, functional protection from SARS-CoV-2 infection and disease. In this study, we explored directly the protective efficacy of human antibodies elicited by Ad26.COV2.S vaccination by adoptive transfer studies. IgG from plasma of Ad26.COV2.S vaccinated individuals was purified and transferred into naive golden Syrian hamster recipients, followed by intra-nasal challenge of the hamsters with SARS-CoV-2. IgG purified from Ad26.COV2.S-vaccinated individuals provided dose-dependent protection in the recipient hamsters from weight loss following challenge. In contrast, IgG purified from placebo recipients provided no protection in this adoptive transfer model. Attenuation of weight loss correlated with binding and neutralizing antibody titers of the passively transferred IgG. This study suggests that Ad26.COV2.S-elicited antibodies in humans are mechanistically involved in protection against SARS-CoV-2.
Fig. 1  Ad26.COV2.S vaccine elicits binding and neutralizing antibodies in plasma and purified IgG from human vaccine recipients. a  Schematic of the experimental design. Participants in the COV1001 clinical trial were vaccinated with Ad26.COV2.S or placebo control. On day 71, plasma samples were collected and total IgG was purified. IgG was then transferred into naive hamster recipients, followed by intra-nasal challenge with WA1/2020 SARS-CoV-2. b–d  Binding and neutralizing activity was quantified in human plasma samples and corresponding IgG purified from plasma samples from either placebo recipients (N = 5) or recipients of the Ad26.COV2.S vaccine at the indicated dosing regimens (N = 20). Binding antibody responses were quantified via electrochemiluminescent assay (ECLA) specific for (b) WA1/2020 SARS-CoV-2 spike (S) protein and (c) WA1/2020 SARS-CoV-2 receptor binding domain (RBD) protein. d  Similarly, neutralizing antibody titers were quantified using a pseudovirus neutralization assay. Data displayed indicate the 50% neutralization titer (NT50) of a WA1/2020 SARS-CoV-2 S-expressing pseudovirus. In panels a–c, each data point displayed corresponds to one clinical trial study participant and red lines indicate the group medians. e–g  Correlation of (e) S binding, (f) RBD binding, and (g) pseudovirus neutralizing antibody titers in pre-purification human plasma and corresponding purified IgG. In panels a–c, each data point displayed corresponds to one clinical trial study participant. Statistics indicate the results of Spearman correlation analysis. h–j  Purified IgG from vaccinees or placebo recipients was transferred to groups of naive hamsters (n = 4–5 hamsters/study participant) via intraperitoneal injection. One day post-transfer, hamster serum was collected and analyzed for (h) S binding, (i) RBD binding, or (j) pseudovirus neutralizing antibody titers. Data points displayed in panels h–j correspond to the median titer of each group of n = 4–5 hamsters that corresponds to one clinical trial study participant. Horizontal red lines indicate medians of groups corresponding to vaccinees or placebo recipients. Statistics displayed are the results of two-sided Mann–Whitney tests. (****P ≤ 0.0001).
In vaccinees, however, detectable 50% neutralizing titers (NT50) were observed in 19/20 plasma samples and 18/20 purified IgG stocks. Pre-purification plasma and purified IgG exhibited similar median NT50 values of 204 and 215, respectively. Further, a strong positive correlation was observed between pre- and post-purification S binding titers (Fig. 1c; R = 0.8215, P < 0.0001), RBD binding titers (Fig. 1f; R = 0.7721, P < 0.0001), and pseudovirus neutralizing antibody titers (Fig. 1g; R = 0.8252, P < 0.0001), demonstrating that the purified IgG retained the binding and neutralizing capacity of original plasma samples.

**Passive transfer of IgG to naïve hamster recipients**

We then assessed the protective efficacy of these purified IgG stocks in an adoptive transfer study in golden Syrian hamsters. For each study participant, 4–5 hamsters received an intra-peritoneal injection of 25 mg of purified IgG. Experimental controls included groups of hamsters that received buffer alone as negative controls (n = 15) or 25 mg of IgG purified from convalescent re-challenged non-human primates (NHPs) after two rounds of SARS-CoV-2 challenge as high-titer positive controls (n = 11). One day after administration of IgG or buffer control, serum was collected from all hamsters to quantify post-transfer, pre-challenge SARS-CoV-2 spike-binding and neutralizing antibody titers. As expected, low or undetectable binding antibody titers to S (Fig. 1h, Supplementary Fig. 1) and RBD (Fig. 1i, Supplementary Fig. 1) proteins were observed in hamsters administered with IgG from placebo recipients, as well as in hamsters that received the buffer control (Supplementary Fig. 1). In contrast, detectable binding titers were observed in all groups of hamsters that received IgG from vaccine recipients, with median titers of 2.8 × 10^3 and 1.2 × 10^3 for S and RBD binding, respectively. Similarly, low or undetectable neutralizing titers were observed in groups of hamsters administered IgG from placebo recipients or buffer only control (Fig. 1), Supplementary Fig. 1). In groups of hamsters that received IgG from vaccine recipients, detectable neutralizing titers were observed in groups corresponding to 12/20 participants who received Ad26.COV2.S SARS-CoV-2 challenge and monitoring of clinical disease

All recipient hamsters were then challenged with 2 × 10^5 TCID50 of WAI/2020 SARS-CoV-2 via the intranasal route. Hamsters were monitored for fourteen days post-challenge for body weight loss. In the negative control group (hamsters receiving buffer only), animals exhibited significant weight loss over approximately seven days, followed by a gradual recovery by day 14 (Fig. 2a, Supplementary Fig. 3). Similarly, in hamsters that received IgG purified from placebo recipients, comparable severe weight loss was observed (Fig. 2a, Supplementary Fig. 3). In contrast, hamsters
that received convalescent NHP IgG exhibited attenuated weight loss (Fig. 2b, Supplementary Fig. 3).

To quantitate protective efficacy across experimental groups, the maximum body weight change was calculated for each group of hamsters, each of which corresponded to one human vaccine recipient. The median peak body weight loss of placebo recipients (−16.0%) was greater than vaccine recipients (−12.0%) (Fig. 2c, P = 0.0192, Mann–Whitney test). Similar analyses were conducted analyzing the peak weight loss of each individual hamster (Fig. 2d, Supplementary Fig. 4). In hamsters that received buffer only, median maximum weight loss was 17.1%. In groups that received IgG from placebo recipients, no significant impact was observed with a median maximum weight loss of 16.5% (P > 0.9999, Kruskal–Wallis test with Dunn’s correction for multiple comparisons). In contrast, recipients of the positive control high-titer IgG from convalescent, re-challenged NHPs exhibited significantly reduced peak weight loss of 5.5% (P < 0.0001, Kruskal–Wallis test with Dunn’s correction for multiple comparisons). Moreover, in groups that received IgG purified from Ad26.COV2.S recipients, reduced median peak weight loss of 12.2% was observed (P = 0.0002, Kruskal–Wallis test with Dunn’s correction for multiple comparisons).

**Analyses of immune correlates of protection**

To characterize the correlation between antibody titer and protective efficacy, a correlation analysis was performed between pre-challenge serum SARS-CoV-2 spike binding or neutralizing titers in the recipient hamsters and post-challenge maximum body weight change (Fig. 3a–g). When analyzing the median values of each hamster group corresponding to one clinical trial participant, significant correlations were observed between body weight loss and S binding (Fig. 3a; R = 0.7985, P < 0.0001), RBD binding (Fig. 3b; R = 0.7830, P < 0.0001), and pseudovirus neutralizing (Fig. 3c; R = 0.6321, P = 0.0007) antibody titers. Significant correlations were also observed through similar analyses of each individual hamster between peak weight loss and S binding (Fig. 3d; R = 0.5022, P < 0.0001), RBD binding (Fig. 3e; R = 0.4834, P < 0.0001) and pseudovirus neutralizing (Fig. 3f; R = 0.5264, P < 0.0001) antibody titers. An additional analysis confirmed that inclusion of the control groups generated similar correlations (Fig. 3g, R = 0.6187, P < 0.0001). Together, these data demonstrate that vaccine-elicited SARS-CoV-2-specific spike binding and neutralizing antibody titers correlated with protection against SARS-CoV-2 challenge following adoptive transfer in hamsters.
DISCUSSION
Our data demonstrate that passive transfer of purified polyclonal IgG from Ad26.COV2.S vaccinated humans confers protection from weight loss following high-dose SARS-CoV-2 challenge in hamsters. These data demonstrate directly and mechanistically that SARS-CoV-2-specific binding and neutralizing antibodies from vaccinated humans have protective capacity. While previous studies have revealed that antibody titers, particularly neutralizing antibody titers, are statistical correlates of protection\cite{16,17,18}, study of the function of vaccine-elicited antibodies from humans remains an underexplored question. This approach has previously been applied for vaccine development for Zika virus\cite{16,19} and other pathogens to isolate and study the role of vaccine-elicited antibodies from human clinical trial participants. Further, in the context of the COVID-19 pandemic, enhanced understanding of key immune signatures that underscore protection could enable evaluation of novel candidate vaccines in the absence of large-scale placebo-controlled clinical trials\cite{5,6,16}.

In this study, a high-dose challenge in golden Syrian hamsters was employed to model severe clinical disease. Towards this goal, hamsters were monitored for two weeks post-challenge for weight loss, limiting the potential to analyze viral loads in tissues at the time of peak viral replication. Future studies could be designed to focus more directly on the potential for transferred IgG to drive virologic control in respiratory tract tissues. The stringency of this challenge model, together with the 10-fold dilution of antibody titers following adoptive transfer, likely explain the incomplete protection observed. Moreover, adoptive transfer of purified IgG excludes the potential contribution of T cell responses to protection. In addition, anamnestic responses are absent in the adoptive transfer model, requiring antibodies at the time of challenge to protect against severe disease without immunologic memory recall responses.

Protection correlated with pre-challenge binding and neutralizing titers post-IgG transfer. Confirmation of such an antibody correlate of protection can support the development and characterization of new vaccines or antibody-based therapeutics, as well as inform public health strategies\cite{19}. However, other immunologic parameters, including Fc functional antibodies, cellular immune responses, and innate parameters may also contribute to protection. Our findings that antibody titers mediate protection against severe disease is consistent with recently-reported large-scale Ad26.COV2.S efficacy trials\cite{16}. These data revealed significant protection from severe COVID-19, with efficacy of 86%, 88%, and 82% in the United States, Brazil, and South Africa, respectively\cite{16}.

Taken together, our data demonstrate that binding and neutralizing antibodies following Ad26.COV2.S vaccination in humans directly contribute to protective efficacy against SARS-CoV-2 in a titer-dependent fashion in a preclinical adoptive transfer model. However, Fc-mediated activity of vaccine induced antibodies may be absent when human IgG is transferred to hamster recipients\cite{16}, and T cell responses have also been reported to contribute to protection in pre-clinical and clinical studies\cite{19,20}. Future studies could explore the role of Ad26.COV2.S-elicited T cell responses or other aspects of the adaptive immune response (e.g., IgG subclass, isotype) in mediating protection against SARS-CoV-2 infection and disease.

METHODS
Clinical study design and human plasma samples
Plasma samples were collected from participants in Cohort 1b of as part of the Phase 1/2a clinical trial of Ad26.COV2.S vaccine (NCT04436276)\cite{12}. This study was conducted at a single site at Beth Israel Deaconess Medical Center in Boston with review and approval by the Beth Israel Deaconess Medical Center institutional review board. All participants gave written informed consent and successfully completed an assessment of understanding before the initiation of study procedures. This descriptive study was performed as part of a larger multicenter, randomized, double-blind, placebo-controlled phase 1/2a trial to evaluate the safety, reactogenicity, and immunogenicity of Ad26.COV2.S at 5 × 10^{10} or 1 × 10^{11} viral particle doses. Vaccines was administered intramuscularly as either a single-shot or 2-shot vaccine schedules, 56 days apart, in healthy adults. Cohort 1b enrolled adults 18 to 55 years of age (N = 25).

IgG purification
Polyclonal IgG was purified from human plasma samples collected on day 71, two weeks after the second immunization of either Ad26.COV2.S or placebo. This purification was conducted using NAB Protein G spin columns (Thermo Scientific). Protein G columns were preconditioned with Protein G IgG Binding Buffer (Thermo Scientific) and plasma samples were added to columns and incubated for 1 h. Columns were then washed, followed by elution with IgG Elution Buffer (Thermo Scientific). Eluted, purified IgG was buffer exchanged with 1 x DPBS and characterized by SDS-PAGE and spectrophotometry was used to quantify yield and normalize stocks to 10 mg/mL\cite{16}.

Electrochemiluminescence assay (ECLA)
ECLA plates to quantify binding antibody responses to WA1/2020 spike (S) and Receptor Binding Domain (RBD) proteins were selected (Mesoscale Discovery SARS-CoV-2 IgG Cat No: N05SCA-1; Panel 11, 13)\cite{16}. Plates were blocked with 50 μL of Blocker A (1% BSA in distilled water) for 30 min at room temperature shaking at 700 rpm with a digital microplate shaker. During blocking the serum was diluted 1:5,000 in Diluent 100. The plates were washed washed 3 times with 150 μL of wash buffer (0.5% Tween in 1X PBS) per well, blotted dry, and 50 μL of the pre-diluted samples were added in duplicate to the plates and set to shake at 700 rpm at room temperature for at least 2 h. The plates were again washed 3 times and 50 μL of SULFO-Tagged anti-Human IgG detection antibody was added to each well was added to each well and incubated shaking at 700 rpm at room temperature for at least 1 h. Plates were then washed 3 times and 150 μL of MSD GOLD Read Buffer B was added to each well and the plates were read immediately after a MESO QuickPlex SQ 120 machine. MSD titers for each sample was reported as Relative Light Units (RLU) which were calculated as average Sample RLU minus Blank RLU for each sample. The limit of detection was defined as 100 RLU for each assay.

Pseudovirus neutralization assay
A SARS-CoV-2 pseudovirus, incorporating a luciferase reporter gene, was generated similar to previously described approaches\cite{1,2,21}. To generate pseudoviruses, HEK293T cells were co-transfected with packaging con- struct pPAX2 (AIDS Resource and Reagent Program), a luciferase reporter plasmid pLenti-CMV Puro-Luc (Addgene), and a plasmid expressing S protein, pcDNA3.1-SARS-CoV-2 SACT with lipofectamine 2000. 48 h after transfection, supernatants containing pseudoviruses were collected and filtered through a 0.45-μm filter. To quantify neutralizing activity of human plasma samples or purified IgG stocks, HEK293T target cells, transfected to express human ACE2 (HEK293T-hACE2), were seeded in 96-well tissue culture plates at a density of 1.75 × 10^{4} cells per well and cultured overnight. Three-fold serial dilutions of heat-inactivated plasma or purified IgG samples were prepared, mixed with 50 μL of pseudovirus, incubated for 1 h at 37 °C, and then added to HEK293T-hACE2 seeded wells. After 48 h of incubation, cells were lysed in Steady-Glo Luciferase Assay Reagent (Promega) according to the manufacturer’s instructions. SARS-CoV-2 neutralizing titers were determined as the sample dilution at which a 50% reduction in relative light units was observed relative to the average of the control wells treated with virus only.

Hamster study design
One-hundred and forty-six male and female Syrian golden hamsters (Envigo), 10–12 weeks old, were randomly allocated to groups. On day 1, animals received an intra-peritoneal injection containing either 25 μg of purified IgG in 2.5 mL of buffer, or 2.5 mL of buffer alone. On day 0, blood was collected via the retro-orbital route to quantify post-transfer serum neutralizing antibodies. Immediately following blood draw, all animals were challenged with 1.99 × 10^{4} TCID_{50}. SARS-CoV-2, which was derived with one passage from USA-WA1/2020 (NR- 53780, BEI Resources). Virus was administered intramuscularly as either a single-shot or 2-shot vaccine schedules, 56 days apart, in healthy adults. Cohort 1b enrolled adults 18 to 55 years of age (N = 25).

Published in partnership with the Sealy Institute for Vaccine Sciences

L.H. Tostanoski et al.

npj Vaccines (2022) 2

Published in partnership with the Sealy Institute for Vaccine Sciences
weight on the day of challenge was established as a humane endpoint euthanasia criteria. Due to the large N, the study was broken down into three cohorts, with a negative control (i.e., buffer only) and a positive control (convalescent NHP IgG) group included in each of the three experiments. Data presented for the control groups are pooled from the three independent challenge studies, which each exhibited similar results.

Ethical statement
All animal studies were conducted in compliance with all relevant local, state, and federal regulations. All experiments were approved by the Bioqual Institutional Animal Care and Use Committee (IACUC).

Reporting Summary
Further information on research design is available in the Nature Research Reporting Summary linked to this article.

DATA AND MATERIALS AVAILABILITY
All data are available in the main text or the supplementary materials.

Received: 4 October 2021; Accepted: 14 December 2021;
Published online: 10 January 2022

REFERENCES
1. Mercado, N. B. et al. Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques. Nature 586, 583–588 (2020).
2. Yu, J. et al. DNA vaccine protection against SARS-CoV-2 in rhesus macaques. Science 369, 806–811 (2020).
3. He, X. et al. Low-dose Ad26.COV2.S protection against SARS-CoV-2 challenge in rhesus macaques. Cell 184, 3467–3473.e3411 (2021).
4. van der Lubbe, J. E. M. et al. Ad26.COV2.S protects Syrian hamsters against G614 spike variant SARS-CoV-2 and does not enhance respiratory disease. NPJ Vaccines 6, 39 (2021).
5. Gottlieb, R. L. et al. Effect of Bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial. JAMA 325, 632–644 (2021).
6. Corti, D., Purcell, L. A., Snell, G. & Veesler, D. Tackling COVID-19 with neutralizing monoclonal antibodies. Cell 184, 3086–3108 (2021).
7. Cohen, M. S. et al. Effect of Bamlanivimab vs Placebo on incidence of COVID-19 among residents and staff of skilled nursing and assisted living facilities: a randomized clinical trial. JAMA 326, 46–55 (2021).
8. McMahen, K. et al. Correlates of protection against SARS-CoV-2 in rhesus macaques. Nature 590, 630–634 (2020).
9. Bos, R. et al. Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses. NPJ Vaccines 5, 9 (2020).
10. Tostanoski, L. H. et al. Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters. Nat. Med. 26, 1694–1700 (2020).
11. Sadoff, J. et al. Interim results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 vaccine. N. Engl. J. Med. 384, 1824–1835 (2021).
12. Stephenson, K. E. et al. Immunogenicity of the Ad26.COV2.S vaccine for COVID-19. JAMA 325, 1535–1544 (2021).
13. Alter, G. et al. Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans. Nature https://doi.org/10.1038/s41586-021-03681-2 (2021).
14. Sadoff, J. et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. N. Engl. J. Med. 384, 2187–2201 (2021).
15. Yu, J. et al. Deletion of the SARS-CoV-2 spike cytoplasmic tail increases infectivity in pseudovirus neutralization assays. J. Virol. 95, https://doi.org/10.1128/jvi.00044-21 (2021).
16. Corbett, K. S. et al. Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates. Science, eabj2299, https://doi.org/10.1126/science.abj2299 (2021).
17. Larocca, R. A. et al. Vaccine protection against Zika virus from Brazil. Nature 536, 474–478 (2016).
18. Salisch, N. C. et al. A double-blind, randomized, placebo-controlled Phase 1 Study of Ad26.ZIKV.001, an Ad26-Vectored Anti-Zika Virus vaccine. Ann. Intern. Med. 174, S58–S59 (2021).
19. Krammer, F. A correlate of protection for SARS-CoV-2 vaccines is urgently needed. Nat. Med. 27, 1147–1148 (2021).
20. Mallajosyula, V. et al. CD8+ T cells specific for conserved coronavirus epitopes correlate with milder disease in COVID-19 patients. Sci. Immunol. 6, eabg5669 (2021).
21. Yu, J. et al. Deletion of the SARS-CoV-2 spike cytoplasmic tail increases infectivity in pseudovirus neutralization assays. J. Virol. https://doi.org/10.1128/jvi.00044-21 (2021).

ACKNOWLEDGEMENTS
We thank the participants in the COV1001 clinical trial, the study investigators and staff in the Center for Virology and Vaccine Research (CVVR) Clinical Trial Unit, the personnel in the CVVR Clinical Research Processing Laboratory, and the Janssen clinical study team. We thank Carla Truysers for advice on statistical analyses. We thank MesoScale Discovery for providing the ECLA kits. We acknowledge funding from Janssen Vaccines & Prevention BV, Biomedical Advanced Research and Development Authority (BARDA; HHS010201700018C), National Institutes of Health (AI007387, CA260476), Massachusetts Consortium on Pathogen Readiness (MassCPRR), and Ragon Institute of MGH, MIT, and Harvard.

AUTHOR CONTRIBUTIONS
L.H.T., F.W., R.C.Z., H.S., and D.H.B. designed the studies. L.H.T., A.C., S.P., J.Y., C.J.D., A.C., O.C.P., D.S., S.G., J.B., O.S. performed the immunologic assays. K.E.S., J.L.A., K.J., M.S.S. coordinated the collection and processing of samples from clinical trial participants. M.P., M.L., B.S., K.C., D.N., S.H., H.B., S.K., H.A., and M.G.L. led the clinical care of the animals. F.C., J.T.B.M.T., A.M.G., D.H., M.L.G., J.S., F.W., R.C.Z., and H.S. provided the vaccine and assisted with data management and analyses. L.H.T. and D.H.B. prepared the figures and wrote the paper with input from all co-authors.

COMPETING INTERESTS
D.H.B., R.C.Z., F.W. and H.S. are co-inventors on provisional vaccine patents (63/121,482; 63/133,969; 63/135,182). F.C., J.T.B.M.T., A.M.G., D.H., M.L.G., J.S., F.W., R.C.Z., and H.S. are employees of Janssen Vaccines & Prevention BV and may hold stock in Johnson & Johnson.

ADDITIONAL INFORMATION
Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41541-021-00427-z.
Correspondence and requests for materials should be addressed to Dan H. Barouch.
Reprints and permission information is available at http://www.nature.com/reprints
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022